Malte Roerden1, Juliane S Walz2, Martin R Müller1, Martin Sökler1, Birgit Federmann3, Lothar Kanz1, Wolfgang Bethge1, Wichard Vogel1. 1. Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Otfried-Müller-Str. 10, 72076, Tübingen, Germany. 2. Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Otfried-Müller-Str. 10, 72076, Tübingen, Germany. juliane.walz@med.uni-tuebingen.de. 3. Department of Pathology and Neuropathology, University Hospital Tübingen, Tübingen, Germany.
Abstract
PURPOSE: Peripheral T cell lymphomas (PTCL) are a rare and heterogeneous group of aggressive non-Hodgkin lymphomas, showing a generally poor prognosis. In this retrospective analysis, we aimed to investigate the impact of autologous stem cell transplantation (autoSCT) in PTCL. METHODS: A retrospective analysis of 58 consecutive unselected PTCL patients aged 21-71 years undergoing autoSCT as first-line consolidation as well as in the relapse setting was performed. RESULTS: The median follow-up time was 67 months. A 5-year overall survival (OS) of 53% and a 5-year progression-free survival (PFS) after autoSCT of 44% was achieved. The overall relapse rate after autoSCT was 50%. On multivariate analysis, standard baseline characteristics such as age, disease stage and international prognostic index (IPI) score failed to predict outcome in our cohort. First-line treatment with autoSCT was not associated with a benefit in OS when compared to patients receiving autoSCT at relapse. Notably, autoSCT seemed to be a suitable approach even for older transplant-eligible patients (aged ≥ 60 years), with a similar 5-year OS of 49% when compared to younger patients. CONCLUSIONS: Our study suggests that autoSCT can achieve long-term survival in PTCL patients even after relapse and should also be considered for eligible older patients.
PURPOSE: Peripheral T cell lymphomas (PTCL) are a rare and heterogeneous group of aggressive non-Hodgkin lymphomas, showing a generally poor prognosis. In this retrospective analysis, we aimed to investigate the impact of autologous stem cell transplantation (autoSCT) in PTCL. METHODS: A retrospective analysis of 58 consecutive unselected PTCL patients aged 21-71 years undergoing autoSCT as first-line consolidation as well as in the relapse setting was performed. RESULTS: The median follow-up time was 67 months. A 5-year overall survival (OS) of 53% and a 5-year progression-free survival (PFS) after autoSCT of 44% was achieved. The overall relapse rate after autoSCT was 50%. On multivariate analysis, standard baseline characteristics such as age, disease stage and international prognostic index (IPI) score failed to predict outcome in our cohort. First-line treatment with autoSCT was not associated with a benefit in OS when compared to patients receiving autoSCT at relapse. Notably, autoSCT seemed to be a suitable approach even for older transplant-eligible patients (aged ≥ 60 years), with a similar 5-year OS of 49% when compared to younger patients. CONCLUSIONS: Our study suggests that autoSCT can achieve long-term survival in PTCL patients even after relapse and should also be considered for eligible older patients.
Authors: B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos Journal: J Clin Oncol Date: 1999-04 Impact factor: 44.544
Authors: F d'Amore; P Gaulard; L Trümper; P Corradini; W-S Kim; L Specht; M Bjerregaard Pedersen; M Ladetto Journal: Ann Oncol Date: 2015-09 Impact factor: 32.976
Authors: P Corradini; C Tarella; F Zallio; A Dodero; M Zanni; P Valagussa; A M Gianni; A Rambaldi; T Barbui; S Cortelazzo Journal: Leukemia Date: 2006-07-27 Impact factor: 11.528
Authors: Henrik Cederleuf; Lasse Hjort Jakobsen; Fredrik Ellin; Peter de Nully Brown; Thomas Stauffer Larsen; Martin Bøgsted; Thomas Relander; Mats Jerkeman; Tarec Christoffer El-Galaly Journal: Leuk Lymphoma Date: 2017-03-20
Authors: Greg Dueck; Neil Chua; Angeli Prasad; Daygen Finch; Doug Stewart; Darrell White; Richard van der Jagt; James Johnston; Andrew Belch; Tony Reiman Journal: Cancer Date: 2010-10-01 Impact factor: 6.860
Authors: Dai Chihara; Michelle A Fanale; Roberto N Miranda; Mansoor Noorani; Jason R Westin; Loretta J Nastoupil; Fredrick B Hagemeister; Luis E Fayad; Jorge E Romaguera; Felipe Samaniego; Francesco Turturro; Hun J Lee; Sattva S Neelapu; M Alma Rodriguez; Michael Wang; Nathan H Fowler; Richard E Davis; L Jeffrey Medeiros; Chitra Hosing; Yago L Nieto; Yasuhiro Oki Journal: Br J Haematol Date: 2016-12-16 Impact factor: 6.998
Authors: S H Advani; K A Dinshaw; C N Nair; R Gopal; G V Talwalkar; Y S Iyyer; H M Bhatia; P B Desai Journal: Cancer Date: 1980-06-01 Impact factor: 6.860
Authors: Francesco d'Amore; Thomas Relander; Grete F Lauritzsen; Esa Jantunen; Hans Hagberg; Harald Anderson; Harald Holte; Anders Österborg; Mats Merup; Peter Brown; Outi Kuittinen; Martin Erlanson; Bjørn Østenstad; Unn-Merete Fagerli; Ole V Gadeberg; Christer Sundström; Jan Delabie; Elisabeth Ralfkiaer; Martine Vornanen; Helle E Toldbod Journal: J Clin Oncol Date: 2012-07-30 Impact factor: 44.544
Authors: Paolo Corradini; Anna Dodero; Francesco Zallio; Daniele Caracciolo; Marco Casini; Marco Bregni; Franco Narni; Francesca Patriarca; Mario Boccadoro; Fabio Benedetti; A Rambaldi; Alessandro M Gianni; Corrado Tarella Journal: J Clin Oncol Date: 2004-06-01 Impact factor: 44.544
Authors: Milos D Miljkovic; Christopher Melani; Stefania Pittaluga; Rahul Lakhotia; Nicole Lucas; Allison Jacob; Erik Yusko; Elaine S Jaffe; Wyndham H Wilson; Mark Roschewski Journal: Blood Adv Date: 2021-10-26